Pinnacle Clinical Research

A clinical trial site network generates revenue by conducting pharmaceutical studies on behalf of drug sponsors — enrolling patients, administering protocols, and collecting data. A healthcare investment firm deploys capital into companies or assets with the goal of financial returns for limited partners. Pinnacle belongs to the first category: it is an operating services company, not a fund, and does not report capital commitments or investment performance.

Pinnacle concentrates on gastroenterology and metabolic diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and related metabolic conditions. These indications require specialized patient recruitment and diagnostic capabilities — including liver biopsy and advanced imaging — that generalist sites often cannot support at scale.

Pinnacle runs trials from Phase I through Phase IV. Phase I work involves first-in-human safety studies in healthy volunteers or patients, while Phase II and III focus on dose-finding and registrational efficacy. Phase IV post-marketing studies round out the portfolio, providing pharmaceutical sponsors with a single-site network for the full development lifecycle.

The firm operates multiple clinical sites in Texas, anchored around its San Antonio headquarters, with additional locations in other US states. The multi-site model allows access to diverse patient populations and investigator specialties, which is increasingly required by pharmaceutical sponsors seeking representative trial enrollment data.

No. Pinnacle is an independent clinical trial site operator — a services business, not a capital allocator. It does not manage a fund, report assets under management, or disclose limited partner relationships. Any wealth tied to the firm's ownership would stem from operating income rather than investment returns on managed third-party capital.